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Rises in cytosolic Ca2+ concentration ([Ca2+]cyt) are central in platelet activation, yet many 
aspects of the underlying mechanisms are poorly understood. Most studies examine how 
experimental manipulations affect agonist-evoked rises in [Ca2+]cyt, but these only monitor 
the net effect of manipulations on the processes controlling [Ca2+]cyt  (Ca
2+ buffering, 
sequestration, release, entry and removal), and cannot resolve the source of the Ca2+ or the 
transporters or channels affected. To investigate the effects of protein kinase C (PKC) on 
platelet Ca2+ signalling, we here monitor Ca2+ flux around the platelet by measuring net Ca2+ 
fluxes to or from the extracellular space and the intracellular Ca2+ stores, which act as the 
major sources and sinks for Ca2+ influx into and efflux from the cytosol, as well as 
monitoring the cytosolic Na+ concentration ([Na+]cyt), which influences platelet Ca
2+ fluxes 
via Na+/Ca2+ exchange. The intracellular store Ca2+ concentration ([Ca2+]st) was monitored 
using Fluo-5N, the extracellular Ca2+ concentration ([Ca2+]ext) was monitored using Fluo-4 
whilst [Ca2+]cyt and [Na
+]cyt were monitored using Fura-2 and SFBI respectively. PKC 
inhibition using Ro-31-8220 or bisindolylmaleimide I potentiated ADP- and thrombin-
evoked rises in [Ca2+]cyt in the absence of extracellular Ca
2+.  PKC inhibition potentiated 
ADP-evoked but reduced thrombin-evoked intracellular Ca2+ release and Ca2+ removal into 
the extracellular medium. SERCA inhibition using thapsigargin and 2,5-di(tert-butyl) l,4-
benzohydroquinone abolished the effect of PKC inhibitors on ADP- evoked changes in 
[Ca2+]cyt  but only reduced the effect on thrombin-evoked responses. Thrombin evokes 
substantial rises in [Na+]cyt which would be expected to reduce Ca
2+ removal via the Na+/Ca2+ 
exchanger (NCX). Thrombin-evoked rises in [Na+]cyt were potentiated by PKC inhibition, an 
effect which was not due to altered changes in non-selective cation permeability of the 
plasma membrane as assessed by Mn2+ quench of Fura-2 fluorescence. PKC inhibition was 
without effect on thrombin-evoked rises in [Ca2+]cyt following SERCA inhibition and either 
removal of extracellular Na+ or inhibition of Na+/K+-ATPase activity by removal of 
extracellular K+ or treatment with digoxin. These data suggest that PKC limits ADP-evoked 
rises in [Ca2+]cyt by acceleration of SERCA activity, whilst rises in [Ca
2+]cyt evoked by the 
stronger platelet activator thrombin are limited by PKC through acceleration of both SERCA 
and Na+/K+-ATPase activity, with the latter limiting the effect of thrombin on rises in [Na+]cyt 
and so forward mode NCX activity. The use of selective PKC inhibitors indicated that 
conventional and not novel PKC isoforms are responsible for the inhibition of agonist-evoked 
Ca2+ signalling.  
 









The importance of rises in cytosolic Ca2+ concentration ([Ca2+]cyt) for the adhesion and 
aggregation of human platelets is well established, and this has encouraged significant 
interest in the molecular mechanisms underlying the creation and control of agonist-evoked 
rises in [Ca2+]cyt in these cells. Most studies examine how experimental manipulation of 
channels, transporters or intermediate signalling proteins affect agonist-evoked rises in 
[Ca2+]cyt  in suspensions of Fura-2- or Fluo-4-loaded human platelets. Yet these studies are 
limited by their ability to only monitor the net effect of any experimental manipulation on 
each of the component processes involved in controlling [Ca2+]cyt  (Ca
2+ buffering, 
sequestration, release, entry and removal), and lack the ability to resolve the source of the 
Ca2+ or the transporters or channels affected. Recent work in human platelets has highlighted 
the many pitfalls of drawing conclusions as to the molecular pathways involved in eliciting 
Ca2+ signals based solely on measurements of [Ca2+]cyt [1-3]. 
A simple method for more accurately tracking the Ca2+ flux around the platelet is to measure 
the net Ca2+ fluxes to or from the extracellular space and the intracellular Ca2+ stores, which 
act as the major sources and sinks for Ca2+ influx into and efflux from the cytosol.  We have 
recently developed and validated methods to measure agonist-evoked changes in extracellular 
and intracellular store Ca2+ concentrations ([Ca2+]ext and [Ca
2+]st, respectively) in platelet cell 
suspensions [3, 4], which can be utilized alongside the measurement of agonist-evoked 
changes in [Ca2+]cyt to improve the interpretation of results compared with simple cytosolic 
Ca2+ measurements alone. This methodology has been successfully used to demonstrate how 
the Na+/Ca2+ exchanger acts to create a pericellular source for Ca2+  recycling into the 
platelet, as well as allowing estimation of the Ca2+ buffering capacity of the platelet cytosol 
[3]. 
The study of Ca2+ signalling is complicated by the presence of Ca2+ feedback pathways, in 
which Ca2+-sensitive signalling proteins can simultaneously modulate the activity of a 
number of Ca2+ translocating proteins during the course of Ca2+ signals. In human platelets, 
previous work has demonstrated a significant role for Protein Kinase C (PKC) in negatively 
regulating agonist-evoked Ca2+ signalling [e.g. 5]. However these kinases have a large variety 
of different molecular targets in platelets that could mediate the effect of this kinase on 
platelet Ca2+  signalling, with a number of publications suggesting a variety of mechanisms 
including inhibition of phospholipase C [6, 7], stimulation of inositol-1,4,5-trisphosphate 
(IP3) breakdown [8, 9], stimulation of  the plasma membrane Ca
2+-ATPase (PMCA) [10, 11], 
stimulation of sarco/endoplasmic reticulum Ca2+-ATPases (SERCAs) [12] and in the case of 
ADP, desensitization of the receptor [13]. Since inhibition of PMCAs does not abolish the 
potentiatory effect of PKC inhibitors on thrombin-evoked Ca2+ rises, PMCAs do not appear 
to be involved in the response [14]. However, there is currently no consensus as to which of 
the other above target(s) may be principally responsible for the observed effects of PKC on 
agonist-evoked Ca2+ signalling. 
ADP activates human platelets via actions on two receptors. The P2Y1 receptor couples via 
Gq to phospholipase C-β (PLC-β) leading to the formation of IP3, which releases Ca2+ from 
the dense tubular system (DTS) [15, 16]. The P2Y12 receptor (formerly known as P2T or 
P2AC) couples via Gi to adenylyl cyclase [17] and phosphoinositide 3-kinase [18]. Thrombin 
activates human platelets via the protease-activated receptors (PARs) 1 and 4 [19]. PAR-1 
and PAR-4 couple via Gq to PLC-β resulting in Ca2+ release from the DTS via IP3 formation. 
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In addition, thrombin releases Ca2+ from acidic organelles via the formation of nicotinic acid 
adenine dinucleotide phosphate (NAADP) [4, 20]. 
 
Here we have examined the role of PKC in ADP- and thrombin-evoked Ca2+ signalling in 
human platelets utilizing a more comprehensive analysis of Ca2+ flux around the platelet than 
hitherto in an attempt to better identify the major molecular targets though which PKC 
regulates platelet Ca2+ signalling. We provide evidence that SERCA appears to be a common 
target of PKC during ADP- and thrombin-evoked Ca2+ signalling in human platelets and that 
the Na+/K+-ATPase may act as a secondary PKC target when platelets are stimulated with the 
stronger platelet activator thrombin.  
 
2. Materials and Methods 
2.1.  Materials 
SBFI/AM and Fura-2/AM were from Texas Fluorescence Laboratories (Austin, TX, USA). 
PKCθ/δ inhibitor was from Merck Millipore (Nottingham, UK).  Fluo-5N/AM and Fluo-4 K+ 
salt were from Invitrogen Ltd (Paisley, UK).  Bisindolylmaleimide I (Bisindo I) and 
BCECF/AM were from Tocris Bioscience (Bristol, UK). Gö6976 was from Abcam 
(Cambridge, UK). ADP, apyrase, digoxin, Ro-31-8220, thapsigargin, thrombin and 2,5-
di(tert-butyl) l,4-benzohydroquinone (TBHQ) were from Sigma-Aldrich (Gillingham, UK). 
All other reagents were of analytical grade. 
2.2. Platelet preparation 
 
Blood was collected under written informed consent by venepuncture from healthy drug-free 
volunteers with local ethical committee approval. The experiments conformed to the 
guidelines stated in the Declaration of Helsinki. Platelet-rich plasma prepared as previously 
described [20].  
 
2.3. Cytosolic Ca2+ measurement 
PRP was incubated with 2 μM Fura-2/AM for 45 min at 37 °C. Platelets were collected by 
centrifugation at 350 × g for 20 min and resuspended in HEPES-buffered saline (HBS; 
145 mM NaCl, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 
10 mM D-glucose, 5 mM KCl, 1 mM MgSO4, pH 7.45) supplemented with 0.1% w/v BSA, 
200 μM CaCl2 and 40 μg ml-1 apyrase (supplemented HBS). Fluorescence was recorded from 
1 ml stirred aliquots of platelet suspension at 37 °C using a Cairn Research 
Spectrophotometer (Cairn Research, Faversham, UK) with excitation at 340 and 380 nm and 
emission at 500 nm. Changes in [Ca2+]cyt were monitored using the 340/380 nm fluorescence 
ratio and calibrated according to the method of Grynkiewicz et al. [21].  
2.4. Measurement of Ca2+ release into the extracellular medium  
2.5 µM Fluo-4 K+ salt was added to washed platelets suspended in supplemented HBS 
immediately prior to the start of the experiments.  Fluo-4 fluorescence was recorded with 
excitation at 480 nm and emission at 515 nm, and calibrated as previously described [3].  A 
validation and quantitative analysis of this technique is presented in [3]. Ro-31-8220 and 
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BisIndo I have fluorescent properties at these wavelengths which could be overcome by 
performing calibration experiments in the presence and absence of Ro-31-8220 and BisIndo 
I.   
2.5. Measurement of intracellular store Ca2+ concentration ([Ca2+]st) 
The use of Fluo-5N-loaded platelets to measure [Ca2+]st has previously been described [4]. 
PRP was incubated with 250 nM Fluo-5N/AM for 2 h at 37 °C. Cells were then collected by 
centrifugation at 350 × g for 20 min and resuspended in supplemented HBS to which 100μM 
RGDS was added. RGDS peptide was included in all experiments to prevent aggregation and 
therefore artefactual decreases in Fluo-5N fluorescence. RGDS at this concentration has 
previously been demonstrated not to affect [Ca2+]cyt signals in human platelets [22]. It was not 
possible to calibrate Fluo-5N measurements made in the presence of PKC inhibitors, as there 
were differential fluorescence effects of these drugs at the maximal and minimal 
fluorescences of Fluo-5N. However, it was possible to compensate for this autofluorescence 
to enable comparison of raw fluorescence values by correcting these values by subtracting the 
increase in fluorescence observed after addition of PKC inhibitors to the media at the end of 
Fmin measurements as previously described [4]. 
2.6. Cytosolic Na+ ([Na+]cyt) measurement 
SBFI-loaded platelets were prepared as described previously [23]. SBFI fluorescence 
measurements were made as for Fura-2 above. Changes in [Na+]i were monitored using the 
SBFI 340/380 nm fluorescence ratio.  






+]cyt were quantified by integration of the change in fluorescence 
records from basal with respect to time for 3 min after ADP or thrombin addition. 
2.8. Statistical analysis  
Values stated are mean ± SEM of the number of observations (n) indicated. Analysis of 
statistical significance was performed either using a paired Student's t-test, or a repeated 
measures ANOVA followed by a post hoc Bonferroni multiple comparisons test. P < 0.05 
was considered significant.  
3. Results 
3.1. PKC inhibitors potentiate ADP- and thrombin-evoked increases in [Ca2+]cyt in the 
absence of extracellular Ca2+ 
To keep this initial analysis as simple as possible, all experiments were performed in a Ca2+ 
free medium (1 mM EGTA was added to chelate extracellular Ca2+) to prevent Ca2+ entry 
from contributing to agonist-evoked Ca2+ signals. As previously demonstrated by Strehl et al. 
[5], broad-spectrum PKC inhibitors potentiated the changes in platelet [Ca2+]cyt evoked by 
ADP (50 µM). Pretreament of Fura-2-loaded human platelets for 10 minutes at 37°C with 
Ro-31-8220 (10 µM) or BisIndo I (5 µM) increased [Ca2+]cyt signals to 226.9 ± 9.1% or 230.7 
± 46.4%  of control respectively (Fig. 1A, B; both n  = 7; P <0.05). Similarly, the rises in 
[Ca2+]cyt evoked by thrombin (0.5 units ml
-1) in the absence of extracellular Ca2+ were 
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increased by pretreatment for 10 minutes at 37°C with Ro-31-8220 (10 µM; Fig. 1C; 245.5 ± 
6.1% of control; n = 5, P < 0.05) or BisIndo I (5 µM: Fig. 1D; 206.0 ± 5.8%; n = 6; P < 0.05).   
ADP stimulation of platelets elicits Ca2+ signalling through the activation of the PLC-coupled 
P2Y1 receptor, and is potentiated by activation of the P2Y12-mediated downregulation of 
adenylyl cyclase [21, 23]. Experiments were performed to examine whether P2Y12 activity 
was a prerequisite for PKC-mediated inhibition of ADP-evoked Ca2+ signals. As shown in 
Fig. 1E and Fig. 1F, pretreatment of platelets with the P2Y12 inhibitor, MeSAMP (75 μM), 
reduced ADP-evoked Ca2+ signals to 79.4 ± 5.0% of control (n = 5; P < 0.05), in agreement 
with previous findings [24]. Pretreatment of Fura-2-loaded platelets with 50 µM Ro-31-8220 
was found to elicit the same potentiatory effect in both the presence (179.9 ± 24.0% of 
MeSAMP-treated control; n = 5; P < 0.05) and absence of MeSAMP (174.0 ± 16.1% of 
untreated control; n = 5; P < 0.05). These results demonstrate that the inhibitory effects of 
PKC on ADP-evoked Ca2+ signalling are mediated downstream of P2Y1- and not P2Y12-
receptor stimulation in human platelets.  
Previous work has demonstrated that the inhibitory effects of PKC on thrombin-evoked 
platelet Ca2+ signalling are elicited downstream of the activation of PAR1 but not PAR4 [14]. 
Since ADP can be released from dense granules upon platelet stimulation with thrombin, 
experiments were also performed to examine whether autocrine ADP stimulation plays a role 
in thrombin-evoked Ca2+ release. Pre-treatment of platelets with both MeSAMP (50 µM) and 
the P2Y1 inhibitor, MRS-2179 (75 µM), elicited no significant inhibition of thrombin-evoked 
Ca2+ release (Fig. 1G; 92.8 ± 5.8% of control; n = 6; P = 0.27).  In contrast, this combination 
of inhibitors significantly inhibited thrombin-evoked Ca2+ signals when platelets were 
stimulated in the presence of external Ca2+ (Fig. 1H; 76.7 ± 7.8% of control; n = 6; P < 0.05), 
demonstrating that the inhibitors were functional. These results demonstrate that autocrine 
ADP stimulation was not responsible for PKC-mediated inhibition of thrombin-evoked Ca2+ 
signals under the conditions used in this study. 
3.2. PKC inhibitors potentiate ADP-evoked intracellular Ca2+ release and Ca2+ removal 
into the extracellular medium  
We investigated whether the effects of the PKC inhibitors on ADP- or thrombin-evoked rises 
in [Ca2+]cyt were due to an increase in the net rate of Ca
2+ release from platelet intracellular 
Ca2+ stores [6-9, 12, 13] or a reduction in the rate of removal of Ca2+ into the extracellular 
medium [10, 11]. 
Pretreatment of Fluo-5N-loaded platelets with 10 µM Ro-31-8220 increased the ADP-evoked 
decrease in [Ca2+]st to 242.1 ± 39.9% of control (Fig. 2A ; n  = 8; P < 0.05). ADP-evoked 
Ca2+ removal into the extracellular medium was enhanced after pretreatment with Ro-31-
8220 or BisIndo I (209.6 ± 39.9% or 121.6 ± 8.0% of control respectively; Fig. 2B, C; both n 
= 7; P < 0.05).  These data therefore suggest that the potentiation of ADP-evoked Ca2+ 
release was mediated via the potentiation of net Ca2+ release from intracellular stores, whilst 
the increase in Ca2+ removal was likely to be an indirect, compensatory response to the 
greater rise in [Ca2+]cyt.  
3.3. SERCA inhibition abolishes the effect of PKC inhibitors on ADP- evoked changes in 
[Ca2+]cyt 
Previous work has shown that treatment with phorbol esters, which stimulate PKC, increases 
Ca2+ sequestration in permeabilised platelets [25] and increases the Vmax of SERCA [12]. 
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Therefore we investigated whether the effects of PKC inhibitors on the ADP-evoked rise in 
[Ca2+]cyt  and fall in [Ca
2+]st might be due to a reduction in SERCA activity. This was done by 
examining the effects of concurrent inhibition of PKC and SERCAs (Fig. 3). Inhibition of 
SERCAs was achieved by treatment with a combination of both thapsigargin and TBHQ 
(TGT), to ensure that both the SERCA2b and SERCA3 isoforms present in human platelets 
were fully inhibited, as SERCA3 has previously been reported to be relatively insensitive to 
thapsigargin [26, 27]. Addition of SERCA inhibitors at the same time as ADP potentiated 
ADP-evoked rises in [Ca2+]cyt  (529.0 ± 97.2% of control; n = 5; P  < 0.05) as expected. In the 
presence of SERCA inhibitors, Ro-31-8220 had no significant additional effect on ADP-
evoked rises in [Ca2+]cyt (Fig. 3A; 108.1 ± 4.6% of SERCA-inhibited control; n = 5; P  >  
0.1). However, as expected, Ro-31-8220 still potentiated ADP-evoked rises in [Ca2+]cyt in 
cells from the same preparations not treated with SERCA inhibitors (Fig. 3B; 209.1 ± 14.5% 
of control; n = 5; P < 0.05). These results suggest that PKC upregulates the activity of 
SERCAs during ADP-evoked Ca2+ signals, and that loss of this upregulation can account for 
the potentiation of ADP-evoked rises in [Ca2+]cyt by PKC inhibitors. 
3.4. PKC inhibitors inhibit thrombin-evoked intracellular Ca2+ release and Ca2+ removal 
into the extracellular medium  
In platelets stimulated with the strong activator thrombin, PKC inhibition using BisIndo I 
reduced the net release of Ca2+ from the intracellular stores (35.6 ± 21.0% of control; n = 6; P 
< 0.05; Fig 4A) as well as reducing the thrombin-evoked rise in [Ca2+]ext  (22.0 ± 4.3% or 
31.8 ± 3.2 % of control for BisIndo I or Ro-81-3220 respectively; Fig. 4B, C; n = 7 or 6; both 
P < 0.05). These data suggests that the principal effect of PKC on thrombin-evoked Ca2+ 
signalling is inhibition of Ca2+ removal from the cytosol, whilst the reduced emptying of the 
intracellular stores is likely an indirect response to the greater rise in [Ca2+]cyt (either by 
affecting the electrochemical gradient for Ca2+ release and/or providing a greater supply of 
Ca2+ to sequestration mechanisms such as SERCA). 
3.5. PKC inhibitors potentiate thrombin-evoked changes in [Na+]cyt  
The data presented above suggested that the principal action of PKC in thrombin-stimulated 
platelets was to inhibit Ca2+ removal across the plasma membrane. This Ca2+ flux is mediated 
by both the PMCA and NCX in human platelets [28, 29], with the PMCA providing a high 
affinity, low capacity system and the NCX a low affinity, high capacity system. Thrombin 
evokes substantial rises in [Na+]cyt from around 5 mM to over 27 mM [30], which would be 
expected to influence NCX activity. We therefore investigated the effects of PKC inhibitors 
on thrombin-evoked changes in [Na+]cyt in SBFI-loaded platelets to examine whether there 
was reduced Na+ flux into the cytosol which might be due to reduced NCX activity. 
Surprisingly, pretreatment with BisIndo I (Fig. 5A) or Ro-81-3220 (Fig. 5B) potentiated the 
thrombin-evoked rises in [Na+]cyt to 274.3 ± 9.8% or 287.2 ± 19.8% of control respectively 
(both n = 6, P < 0.05).  Therefore we considered whether the greater rise in [Na+]cyt might be 
responsible for the reduced Ca2+ removal into the extracellular medium observed in the 
previous Fluo-4 experiments, by slowing forward mode Na+/Ca2+ exchange.     
3.6. PKC inhibitors are without effect on thrombin-evoked rises in [Ca2+]cyt following 
SERCA inhibition and removal of extracellular Na+ 
To examine whether greater thrombin-evoked rises in [Na+]cyt were responsible for the effect 
of the PKC inhibitors on [Ca2+]cyt, experiments were conducted in which extracellular Na
+ 
was substituted with the cell-impermeant cation N-methyl-D-glucamine (NMDG).  In 
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addition, we examined the effect of concurrent inhibition of SERCA, to see whether the 
upregulation of SERCA by PKC might also contribute to its effects on the thrombin-evoked 
response as it does with ADP. As previously observed, pretreatment of control cells with Ro-
81-3220 potentiated the thrombin-evoked rise in [Ca2+]cyt  (222.5 ± 13.2% of control; n = 6, P 
< 0.05; Fig. 6A). Replacing extracellular Na+ with NMDG reduced but did not abolish the 
Ro-81-3220-mediated potentiation of the thrombin evoked rise in [Ca2+]cyt (163.9 ± 8.5% of 
control; n = 6, P < 0.05;Fig. 6B). Similarly inhibition of SERCA failed to prevent the 
potentiating effect of Ro-81-3220 on [Ca2+]cyt 
 in thrombin-stimulated platelets (127.0 ± 1.9% 
of control; n = 6, P < 0.05; Fig. 6C).  However, following SERCA inhibition in combination 
with removal of extracellular Na+, pretreatment with Ro 81-3220 was without effect on the 
thrombin evoked rise in [Ca2+]cyt (102.3 ± 2.4% of control, (n = 6, P > 0.05; fig. 6D).  
This result suggests that PKC activity limits thrombin-evoked rises in [Ca2+]cyt by two 
different actions. Firstly PKC activity increases SERCA activity, promoting the uptake of 
Ca2+ into intracellular stores. Secondly, PKC activity reduces the thrombin-evoked rise in 
[Na+]cyt, so reducing inhibition of forward mode Na
+/Ca+ exchange.  
3.7. PKC inhibitors have no effect on the thrombin-evoked opening of non-selective cation 
channels. 
To examine whether the effect of PKC inhibitors on thrombin-evoked rises in [Na+]cyt was 
due to an enhanced permeability of the platelet plasma membrane to cations, we examined 
whether PKC inhibitors altered the thrombin-evoked increase in divalent cation entry 
utilizing Mn2+ quench of Fura-2 fluorescence [31]. Pre-incubating platelets with the PKC 
inhibitors BisIndo I or Ro 81-3220, had no discernible effect on the thrombin evoked Mn2+ 
quench (Fig. 7), which was 100.2±3.7% of control  (n = 6, p > 0.05) after treatment with 
BisIndo I (5 µM; Fig 7A) and 97.3±2.7% of control (n=6, p > 0.05; Fig 7B) after treatment 
with Ro 81-3220 (10 µM). These data demonstrate that PKC is not mediating its inhibitory 
effects on platelet Ca2+ signalling via inhibition of plasma membrane non-selective cation 
channels. 
 
3.8. PKC inhibitors are without effect on thrombin-evoked rises in [Ca2+]cyt following 
SERCA and Na+/K+-ATPase inhibition 
As cation channel opening is not affected and Ca2+ removal across the plasma membrane 
(presumably via the NCX) is inhibited when platelets are preincubated with PKC inhibitors, 
these data suggested that the greater thrombin-evoked rise in [Na+]cyt might be mediated by 
blockade of a PKC-mediated upregulation of Na+/K+-ATPase activity. To test this hypothesis, 
we investigated whether removing extracellular K+ or pretreating cells with Na+/K+-ATPase 
inhibitor digoxin could reverse the effect of PKC inhibitors on [Ca2+]cyt
 when cells were 
concurrently treated with SERCA inhibitors. 
 
To physiologically inhibit the Na+/K+-ATPase, extracellular K+ was replaced with Na+. In 
these platelet preparations under control conditions (K+-containing medium), pretreatment 
with Ro 81-3220 potentiated thrombin-evoked rises in [Ca2+]cyt to 183.0 ± 3.7% of control 
(Fig. 8A; n = 9, P < 0.05) and pretreatment with SERCA inhibitors only partially reduced this 
potentiation to 128.4 ± 4.7% of control (Fig. 8B; n = 9, P < 0.05). In the absence of 
extracellular K+, Ro 81-3220  potentiated thrombin-evoked rises in [Ca2+]cyt to 165.1 ± 5.6% 
of control (Fig. 8C; n = 9, P < 0.05). These results are as would be expected if both SERCA 
and Na+/K+-ATPase activity were concurrently upregulated by PKC upon thrombin 
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stimulation. In contrast, when platelets were stimulated with thrombin in a K+-free medium 
and concurrently treated with SERCA inhibitors, there was no additional effect of Ro 81-
3220 on thrombin-evoked rises in [Ca2+]cyt (98.3 ± 3.2% of the K
+-free and SERCA –
inhibited control; Fig. 8D; n = 9; P > 0.5), suggesting that the Na+/K+-ATPase was 
responsible for mediating the additional effect of PKC on thrombin-stimulated platelets after 
SERCA inhibition. 
To confirm this finding we pharmacologically inhibited the Na+/K+-ATPase, by pretreating 
platelets with digoxin (100 μM) for 1 h at 37°C. Following prolonged incubation at 37°C, 
thrombin-evoked responses were smaller and records more noisy than those observed in 
earlier experiments, probably due to the leak of Fura-2 from the platelets. Under these 
conditions, Ro 81-3220 again potentiated thrombin-evoked rises in [Ca2+]cyt in untreated cells 
to 167.0 ± 10.1% of control (Fig. 9A; n = 6, P < 0.05). Pretreatment with SERCA inhibitors 
reduced this potentiation to 119.6 ± 4.9% of SERCA –inhibited control (Fig. 9B; n = 6, P < 
0.05) and pretreatment with digoxin reduced it to 146.8 ± 8.6% of control (Fig. 9C; n = 6, P < 
0.05). However treatment with both SERCA inhibitors and digoxin abolished the potentiation 
of the thrombin-evoked rise in [Ca2+]cyt by Ro 81-3220 (Fig. 9D; 105.0 ± 3.2% of SERCA 
and digoxin-treated control, n = 6, P > 0.5). This result suggests that the influence of PKC on 
thrombin-evoked rises in [Ca2+]cyt results from combined increased activity of the Na
+/K+-
ATPase and SERCAs. 
3.9 Conventional PKC isoforms mediate inhibitory effects on both ADP- and thrombin-
evoked Ca2+ signalling 
The data presented above using broad-spectrum PKC inhibitors suggest at least two distinct 
roles for this kinase in regulating platelet Ca2+ signalling. However, since human platelets 
possess a number of PKC isoforms [25], there is a possibility that the PKC-dependent effects 
on Na+/K+-ATPase and SERCA activities may be mediated by distinct PKC isoforms. 
Therefore experiments were conducted to examine which isoforms of PKC might be involved 
in mediating these inhibitory effects on platelet Ca2+ signalling. Human platelets are known 
to express both the conventional PKCα and PKCβ isoforms, and the novel PKC isoforms, 
PKCδ and PKCθ [25]. These subgroups of PKC isoforms can be differentiated by the 
response to rises in intracellular Ca2+ concentration, with the classical isoforms being 
regulated by Ca2+ and diacylglycerol binding, whilst the novel isoforms require only 
diacylglycerol to increase their kinase activity [32]. Experiments were therefore performed to 
examine the effects on agonist-evoked Ca2+ signalling of compounds able to differentially 
inhibit the classical isoforms (Gö6976) and novel isoforms (PKCθ/δ inhibitor) expressed in 
human platelets. Previous work has demonstrated that Gö6976 can also inhibit the tyrosine 
kinase, Syk, in platelets [33].  However previous work has shown that the tyrosine kinase 
inhibitor, Genistein which has been shown to inhibit agonist-evoked Syk activation in human 
platelets [34], has no effect on thrombin- or ADP-evoked Ca2+ release [35, 36]. In addition, a 
recent report using a specific Syk inhibitor, PRT-060318, found no effect on TRAP-induced 
Ca2+ signals at concentrations found to inhibit over 90% of the convulxin-induced Ca2+ 
response [37].  These results therefore suggest that any effect of Gö6976 observed on platelet 
Ca2+ signalling is limited to its effect on conventional PKC isoforms. 
Firstly, we examined the effect of the conventional PKC inhibitor, Gö6976, on thrombin- and 
ADP-evoked Ca2+ release.  As shown in Figures 10A and 10C, pretreatment with Gö6976 (3 
μM) potentiated both ADP- (167.5 ± 22.5 % of control; n = 5, P < 0.05) and thrombin-
evoked (174.3 ± 9.8% of control; n = 6, P < 0.05) Ca2+ signals. Similar to our above findings 
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with broad-spectrum PKC inhibitors, the effect of Gö6976 on ADP-evoked Ca2+ signalling 
was abolished by the addition of SERCA inhibitors concomitantly with ADP stimulation 
(101.3 ± 4.2 % of control; Fig.10B; n = 5, P > 0.05).  In contrast, the effect of Gö6976 on 
thrombin-evoked Ca2+ signalling was found to only be partially reduced by either inhibition 
of SERCAs (126.4 ± 3.0 % of control; Fig. 10D; n = 6, P < 0.05), or replacement of 
extracellular Na+ with NMDG (153.6 ± 6.3 % of control; Fig. 10E;  n = 6, P < 0.05). 
However, the combination of both of these treatments was found to abolish the effect of 
Gö6976 on thrombin-evoked Ca2+ signalling (102. ± 22.5 % of control; Fig. 10F; n = 6, P > 
0.05). These findings are in line with our above results using broad-spectrum PKC inhibitors, 
and suggest that conventional PKC isoforms are responsible for the inhibitory effects on both 
SERCAs and the Na+/K+-ATPase.   
PKCθ/δ inhibitor potently inhibits novel PKC isoforms with an IC50 of 70 nM for PKCθ, and 
350 nM for PKCδ, with no notable effect on conventional PKC isoforms (IC50 > 50 μM for 
PKCβ) [38]. Pretreatment of Fura-2-loaded human platelets with PKCθ/δ inhibitor was found 
not to potentiate ADP-evoked Ca2+ release at lower concentrations (100 or 300 nM; 102.9 ± 
5.2 % or 91.4 ± 8.5 % of control; Fig 11A both n = 6 and P > 0.05) and to inhibit ADP-
evoked Ca2+ release at higher concentration (1 or 3 μM; 75.4 ± 8.8% or 53.9 ± 14.5% of 
control; both n = 6 and P < 0.05), suggesting that novel PKC isoforms are not responsible for 
activating SERCA and Na+/K+-ATPase activity in ADP-stimulated platelets. Further 
experiments considered the possibility that the activities of novel and conventional PKC 
isoforms are redundant in modulating ADP- and thrombin-evoked Ca2+ release. Pretreatment 
of platelets with Gö6976 alone induced a significant potentiation of both ADP- (146.7 ± 11.3 
% of control; n = 6; Fig 11B; P < 0.05) and thrombin-evoked Ca2+ signals (168.7 ± 13.3 % of 
control; n = 5; Fig 11C; P < 0.05). In contrast, pretreatment of platelets with PKCθ/δ inhibitor 
(300 nM) had no significant effect on the Ca2+ signals elicited by either agonist (92.2 ± 5.5% 
or 98.5 ± 5.3 % of control for ADP and thrombin respectively; both n = 6 and 5; P > 0.05).  
When used in combination the effect of these two inhibitors was found to lead to a small but 
consistent reduction in the potentiation elicited by Gö6976 alone (122.5 ± 7.7% or 151.2 ± 
10.9 % of control for ADP and thrombin respectively; n = 6 and 5 respectively).   These 
results therefore support our finding that conventional, but not novel, isoforms of PKC are 
involved in mediating the inhibitory effect of PKC on platelet Ca2+ signalling.  
Discussion 
In this study, we have adopted a more rigorous approach for examining Ca2+ signalling in 
platelets than simply monitoring [Ca2+]cyt.  By monitoring the flux of Ca
2+ to and from the 
Ca2+ sources and sinks which supply the cytosol, in addition to monitoring the [Ca2+]cyt 
 itself, 
we have been able to show that while PKC has a negative effect on Ca2+ signalling in ADP- 
and thrombin-stimulated platelets, the principal point of action on this signalling system is 
distinct for these agonists.  Whilst the main effect of PKC on Ca2+ fluxes during ADP-evoked 
signalling appeared to be a reduction in net Ca2+ efflux from intracellular stores, the major 
mode of action of PKC in thrombin-stimulated platelets appeared to be in facilitating Ca2+ 
removal across the plasma membrane. These results highlight the need to look beyond merely 
examining the net effect of any experimental manipulation of the platelet signalling system 
on agonist-evoked rises in [Ca2+]cyt, to examine how these manipulations affect the flux of 
Ca2+ from or into the component Ca2+ sources and sinks. By doing this we have demonstrated 
an agonist-dependent signalling function of the PKC system in human platelets and have 
been better able to design further experiments to pinpoint the molecular pathways affected. 
This has allowed us to demonstrate that PKC upregulates SERCA activity in response to both 
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ADP and thrombin, but that Na+/K+-ATPase activity is also affected when the stronger 
platelet activator thrombin is used (Fig. 12). The reasons for this difference are currently 
unclear but may relate to the lower diacylglycerol concentrations observed in platelets 
stimulated with ADP compared with thrombin [39, 40]. The reduced translocation of PKC to 
the plasma membrane might limit the ability of PKC to significantly alter the activity of 
Na+/K+-ATPase in ADP-stimulated platelets [41, 42]. Future work examining the role of 
modulating diacylglycerol levels in ADP-stimulated platelets might help delineate this 
pathway further [39]. 
By studying the effects of PKC inhibitors that are able to selectively inhibit either the novel 
or conventional PKC isoforms expressed in human platelets, we have provided evidence that 
the negative regulation of ADP- and thrombin-evoked Ca2+ signalling is likely to be 
selectively mediated via conventional PKC isoforms. This is in line with previous data that 
demonstrated a role for PKCβ (but not PKCθ or PKCδ) in inhibiting ADP-evoked Ca2+ 
signals in human platelets [43]. In contrast, treating platelets with an inhibitor of novel PKC 
isoforms appears to suppress the Ca2+ signals elicited by ADP and thrombin. Interestingly, 
previous work has demonstrated that collagen-evoked Ca2+ signalling in human platelets is 
negatively regulated by novel PKC isoforms and positively regulated by conventional PKC 
isoforms [44]. An agonist-specific effect of isoform-selective PKC inhibition has also been 
reported for platelet dense granule secretion [45]. These results beg the question as to 
whether novel PKC isoforms are potentiating collagen-evoked signalling by triggering the 
same effects on SERCA and Na+/K+-ATPase activity elicited by the conventional isoforms 
upon thrombin- or ADP-stimulation, or whether there are distinct molecular targets for PKC 
that modulate collagen-evoked Ca2+ signals.   
Whilst this approach to the study of Ca2+ signalling does provide a better foundation from 
which to explore molecular pathways, there are limitations in that it will only identify the net 
effect of the experimental manipulations on Ca2+ flux to or from intracellular stores and the 
extracellular space. This means that counteracting effects on these fluxes may not show up if 
they cancel themselves out. Thus it is important to note that this analysis only detects the 
principal effects on the Ca2+ signalling system, and we cannot rule out additional effects of 
PKC on the system.   
In addition, whilst we have been able to identify SERCAs and the Na+/K+-ATPase as the 
final targets of PKC in this system, we have no ability to distinguish between the possibility 
that PKC directly regulates the activity of these transporters through phosphorylation, or 
indirectly through an intermediate signalling protein or binding partner.  Thus at this stage we 
can only speculate on how the Na+/K+-ATPase and SERCAs are regulated by PKC.  
Previous work has demonstrated that treatment with PKC-activating phorbol esters increases 
SERCA activity in permeabilised platelets [12]. Although SERCA activity has been reported 
to be increased by PKC activation in others cells [46], we believe our results provide the first 
evidence for the regulation of SERCA by PKC in intact platelets under the control of 
physiological agonists. It is possible that this regulation may be direct as phosphoproteomic 
profiling of platelets has previously shown a serine phosphorylation of SERCA2 [47]. 
However, Tao and colleagues [12] have previously suggested that PKC may affect SERCA 
indirectly via phosphorylation of Rap1b. Given that PKC has been shown to phosphorylate 
and activate Rap1b [48, 49] and that phosphorylation of Rap1b by other kinases is thought to 
regulate SERCA activity in platelets [50-52], Rap1b may be involved in the regulation of 
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SERCA activity by PKC.  Further studies investigating the phosphorylation of SERCA and 
association of Rap1b with SERCA may help distinguish between these possibilities. 
The molecular mechanism by which PKC influences Na+/K+-ATPase activity in platelets is 
less clear. PKC has been reported to increase Na+/K+-ATPase activity in other cell types 
including arterial smooth muscle [53] and cardiac myocytes [54]. However, unlike with 
SERCA, there is no evidence for phosphorylation of this protein in the resting platelet 
phosphoproteome [47], although given the need for activation with a strong platelet activator 
for the Na+/K+-ATPase to be influenced by PKC, phosphorylation of this protein might not be 
expected under resting conditions. In cardiac muscle and several other cell types, Na+/K+-
ATPase activity is modulated by association with members of the FXYD family of proteins 
[55]. However, no members of the FXYD family have been detected in the platelet proteome 
[56]. Another possibility is that there is a change in surface expression of the Na+/K+-ATPase 
in thrombin-stimulated platelets. Surface expression of this transporter has been reported to 
increase more than ten-fold in ADP stimulated platelets as assessed by [3H]-ouabain binding 
[57]. Given the central role of PKC in granule secretion in platelets [32], it is not 
inconceivable that thrombin-evoked activation of PKC may also increase the apparent 
activity of Na+/K+-ATPase through modulation of its expression in the platelet plasma 
membrane.   
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Fig. 1. PKC inhibitors potentiate ADP- and thrombin-evoked increases in [Ca2+]cyt. Fura-2-
loaded human platelets were suspended in supplemented HBS containing 200 µM CaCl2, and 
preincubated with either 10 µM Ro-31-8220 (A,C, E, F), 5 µM BisIndo I (B, D),  75 μM 
MeSAMP (F), 75 μM MesAMP and 75 μM MRS-2179 (G,H) or their vehicle, DMSO as 
indicated, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM 
EGTA (A-G) or extracellular Ca2+ was raised to 1 mM by addition of 800 μM CaCl2 (H) 
before the platelets were stimulated with 50 µM ADP (A, B, E, F) or 0.5 units ml-1 thrombin 
(C, D, G, H).  
Fig. 2. PKC inhibitors potentiate ADP-evoked intracellular Ca2+ release and Ca2+ removal 
into the extracellular medium. A. Fluo-5N –loaded human platelets were suspended in 
supplemented HBS containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or 
the vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 
mM EGTA before the platelets were stimulated with 50 µM ADP. B, C. Washed human 
platelets were suspended in a supplemented HBS containing 200 µM CaCl2, and preincubated 
with either 10 µM Ro-31-8220 (B), 5 µM BisIndo I (C) or their vehicle, DMSO, for 10 min 
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at 37°C. 2.5 µM Fluo-4 K+ salt was then added immediately prior to the start of the 
experiments. Extracellular Ca2+ was chelated by addition of 1 mM EGTA and the platelets 
were then stimulated with 50 µM ADP. 
Fig. 3. SERCA inhibition abolishes the effect of PKC inhibitors on ADP- evoked changes in 
[Ca2+]cyt. Fura-2-loaded human platelets were suspended in supplemented HBS containing 
200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or its vehicle, DMSO, for 10 
minutes at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM EGTA and the 
platelets stimulated with 50 µM ADP and either both SERCA inhibitors, 1 µM thapsigargin 
and 20 µM TBHQ (TGT), or an equal volume of their vehicle, DMSO.  
Fig. 4. PKC inhibitors inhibit thrombin-evoked intracellular Ca2+ release and Ca2+ removal 
into the extracellular medium. A. Fluo-5N-loaded human platelets were suspended in 
supplemented HBS containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or 
the vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 
mM EGTA before the platelets were stimulated with 0.5 units ml-1 thrombin. B, C. Washed 
human platelets were suspended in a supplemented HBS containing 200 µM CaCl2, and 
preincubated with either 10 µM Ro-31-8220 (B), 5 µM BisIndo I (C) or their vehicle, DMSO, 
for 10 min at 37°C. 2.5 µM Fluo-4 K+ salt was then added immediately prior to the start of 
the experiments. Extracellular Ca2+ was chelated by addition of 1 mM EGTA and the platelets 
were then stimulated with 0.5 units ml-1 thrombin. 
Fig. 5. PKC inhibitors potentiate thrombin-evoked changes in [Na+]cyt. SBFI-loaded human 
platelets were suspended in supplemented HBS containing 200 µM CaCl2 and preincubated 
with either 5 µM BisIndo I (A), 10 µM Ro-31-8220 (B) or their vehicle, DMSO, for 10 min 
at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM EGTA and the platelets 
were then stimulated with 0.5 units ml-1 thrombin. 
Fig. 6. PKC inhibitors are without effect on thrombin-evoked rises in [Ca2+]cyt following 
SERCA inhibition and removal of extracellular Na+. Fura-2-loaded human platelets were 
suspended in supplemented HBS (A, C) or a similar medium in which Na+ was replaced with 
NMDG (B, D) containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or its 
vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 
mM EGTA and the platelets stimulated with 0.5 units ml-1 thrombin and either both 1 µM 
thapsigargin and 20 µM TBHQ (TGT), or an equal volume of their vehicle, DMSO. 
Fig. 7. PKC inhibitors have no effect on the thrombin-evoked opening of non-selective cation 
channels. Fura-2-loaded human platelets were suspended in a Ca2+-free medium, and 
preincubated with either 5 µM BisIndo I (A), 10 µM Ro-31-8220 (B) or their vehicle, DMSO 
(A,B), for 10 min at 37°C. 500 μM EGTA was then added followed by the addition of 1 mM 
MnCl2. Platelets were then stimulated with 0.5 units ml
-1 thrombin. An unstimulated control 
sample is also shown in both panels 
Fig. 8. PKC inhibitors are without effect on thrombin-evoked rises in [Ca2+]cyt following 
SERCA and Na+/K+-ATPase inhibition by removal of extracellular K+. Fura-2-loaded human 
platelets were suspended in supplemented HBS (A, C) or a similar medium in which K+ was 
replaced with Na+ (B, D) containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-
8220 or its vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by 
addition of 1 mM EGTA and the platelets stimulated with 0.5 units ml-1 thrombin and either 




Fig. 9. PKC inhibitors are without effect on thrombin-evoked rises in [Ca2+]cyt following 
SERCA and Na+/K+-ATPase inhibition using digoxin. Fura-2-loaded human platelets were 
suspended in supplemented HBS containing 200 µM CaCl2 and preincubated with 100 μM 
digoxin (C, D) or its vehicle, DMSO (A, B), for 1 h at 37°C and 10 µM Ro-31-8220 or its 
vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 
mM EGTA and the platelets stimulated with 0.5 units ml-1 thrombin and either both 1 µM 
thapsigargin and 20 µM TBHQ (TGT; B, D), or an equal volume of their vehicle, DMSO (A, 
C). 
Fig. 10. The conventional PKC isoform inhibitor Gö6976 potentiates ADP- and thrombin-
evoked rises in [Ca2+]cyt. Fura-2-loaded human platelets were suspended in supplemented 
HBS (A-D) or a similar medium in which Na+ was replaced with NMDG (E, F) containing 
200 µM CaCl2 and preincubated with 3 µM Gö6976 or its vehicle, DMSO, for 10 min at 
37°C. Extracellular Ca2+ was then chelated by addition of 1 mM EGTA and the platelets 
stimulated with 50 µM ADP (A, B) or 0.5 units ml-1 thrombin (C-F) and either both 1 µM 
thapsigargin and 20 µM TBHQ (TGT; B, D, F), or an equal volume of their vehicle, DMSO 
(A, C, E).  
 Fig. 11. The novel PKC isoform (PKCθ/δ inhibitor) does not potentiate ADP- or thrombin-
evoked rises in [Ca2+]cyt. (A) Fura-2-loaded human platelets were suspended in supplemented 
HBS containing 200 µM CaCl2, and preincubated with 100 nM, 300 nM, 1 µM or 3 µM 
PKCθ/δ inhibitor or its vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then 
chelated by addition of 1 mM EGTA before the platelets were stimulated with 50 µM ADP. 
(B, C) Fura-2-loaded human platelets were suspended in supplemented HBS containing 200 
µM CaCl2, and preincubated with 300 nM PKCθ/δ inhibitor, 3 µM Gö6976, both inhibitors 
or their vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition 
of 1 mM EGTA before the platelets were stimulated with 50 µM ADP (B) or 0.5 units ml-1 
thrombin. Results are expressed as mean of percentage control responses. * = P < 0.05 v. 
control, † = P < 0.05. 
Fig. 12. Model for proposed effects of PKC in controlling ADP- and thrombin-evoked Ca2+ 
signalling in human platelets. The agonist-evoked rise in [Ca2+]cyt is controlled by the 
conventional protein kinase C isoforms, PKCα and PKCβ, by altering the rate of Ca2+ 
removal into the extracellular fluid and Ca2+ sequestration into intracellular stores in an 
agonist-dependent manner. Upon ADP activation, PKC negatively regulates the Ca2+ signal 
by increasing Ca2+ sequestration back into the dense tubular system through activation of 
SERCA. Upon thrombin stimulation, PKC additionally regulates Ca2+ removal from the 
cytosol into the extracellular space by increasing the activity of the Na+/K+-ATPase. This in 
turn limits agonist-evoked rises in [Na+]cyt, which slows Ca
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Fig. 1. PKC inhibitors potentiate ADP- and thrombin-evoked increases in [Ca2+]cyt. Fura-2-loaded 
human platelets were suspended in supplemented HBS containing 200 µM CaCl2, and preincubated 
with either 10 µM Ro-31-8220 (A,C, E, F), 5 µM BisIndo I (B, D),  75 μM MeSAMP (F), 75 μM 
MesAMP and 75 μM MRS-2179 (G,H) or their vehicle, DMSO as indicated, for 10 min at 37°C. 
Extracellular Ca2+ was then chelated by addition of 1 mM EGTA (A-G) or extracellular Ca2+ was 
raised to 1 mM by addition of 800 μM CaCl2 (H) before the platelets were stimulated with 50 µM 
ADP (A, B, E, F) or 0.5 units ml-1 thrombin (C, D, G, H) 
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Figure 2                        
 
Fig. 2. PKC inhibitors potentiate ADP-evoked intracellular Ca2+ release and Ca2+ removal into 
the extracellular medium. A. Fluo-5N –loaded human platelets were suspended in supplemented 
HBS containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or the vehicle, DMSO, for 
10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM EGTA before the platelets 
were stimulated with 50 µM ADP. B, C. Washed human platelets were suspended in a supplemented 
HBS containing 200 µM CaCl2, and preincubated with either 10 µM Ro-31-8220 (B), 5 µM BisIndo I 
(C) or their vehicle, DMSO, for 10 min at 37°C. 2.5 µM Fluo-4 K+ salt was then added immediately 
prior to the start of the experiments. Extracellular Ca2+ was chelated by addition of 1 mM EGTA and 
the platelets were then stimulated with 50 µM ADP. 
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Figure 3   
 
Fig. 3. SERCA inhibition abolishes the effect of PKC inhibitors on ADP- evoked 
changes in [Ca2+]cyt. Fura-2-loaded human platelets were suspended in supplemented HBS 
containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or its vehicle, DMSO, 
for 10 minutes at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM EGTA and 
the platelets stimulated with 50 µM ADP and either both SERCA inhibitors, 1 µM 










Fig. 4. PKC inhibitors inhibit thrombin-evoked intracellular Ca2+ release and Ca2+ removal into 
the extracellular medium. A. Fluo-5N-loaded human platelets were suspended in supplemented 
HBS containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or the vehicle, DMSO, for 
10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM EGTA before the platelets 
were stimulated with 0.5 units ml-1 thrombin. B, C. Washed human platelets were suspended in a 
supplemented HBS containing 200 µM CaCl2, and preincubated with either 10 µM Ro-31-8220 (B), 5 
µM BisIndo I (C) or their vehicle, DMSO, for 10 min at 37°C. 2.5 µM Fluo-4 K+ salt was then added 
immediately prior to the start of the experiments. Extracellular Ca2+ was chelated by addition of 1 mM 





Fig. 5. PKC inhibitors potentiate thrombin-evoked changes in [Na+]cyt. SBFI-loaded 
human platelets were suspended in supplemented HBS containing 200 µM CaCl2 and 
preincubated with either 5 µM BisIndo I (A), 10 µM Ro-31-8220 (B) or their vehicle, 
DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM EGTA 







Fig. 6. PKC inhibitors are without effect on thrombin-evoked rises in [Ca2+]cyt following 
SERCA inhibition and removal of extracellular Na+. Fura-2-loaded human platelets were 
suspended in supplemented HBS (A, C) or a similar medium in which Na+ was replaced with 
NMDG (B, D) containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or its 
vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 
mM EGTA and the platelets stimulated with 0.5 units ml-1 thrombin and either both 1 µM 














Fig. 7. PKC inhibitors have no effect on the thrombin-evoked opening of non-selective 
cation channels. Fura-2-loaded human platelets were suspended in a Ca2+-free medium, and 
preincubated with either 5 µM BisIndo I (A), 10 µM Ro-31-8220 (B) or their vehicle, DMSO 
(A,B), for 10 min at 37°C. 500 μM EGTA was then added followed by the addition of 1 mM 
MnCl2. Platelets were then stimulated with 0.5 units ml
-1 thrombin. An unstimulated control 
sample is also shown in both panels 
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Fig. 8. PKC inhibitors are without effect on thrombin-evoked rises in [Ca2+]cyt following 
SERCA and Na+/K+-ATPase inhibition by removal of extracellular K+. Fura-2-loaded 
human platelets were suspended in supplemented HBS (A, C) or a similar medium in which 
K+ was replaced with Na+ (B, D) containing 200 µM CaCl2 and preincubated with 10 µM Ro-
31-8220 or its vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by 
addition of 1 mM EGTA and the platelets stimulated with 0.5 units ml-1 thrombin and either 




Figure 9  
 
 
Fig. 9. PKC inhibitors are without effect on thrombin-evoked rises in [Ca2+]cyt following 
SERCA and Na+/K+-ATPase inhibition using digoxin. Fura-2-loaded human platelets were 
suspended in supplemented HBS containing 200 µM CaCl2 and preincubated with 100 μM 
digoxin (C, D) or its vehicle, DMSO (A, B), for 1 h at 37°C and 10 µM Ro-31-8220 or its 
vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 
mM EGTA and the platelets stimulated with 0.5 units ml-1 thrombin and either both 1 µM 







Fig. 10. The conventional PKC isoform inhibitor Gö6976 potentiates ADP- and 
thrombin-evoked rises in [Ca2+]cyt. Fura-2-loaded human platelets were suspended in 
supplemented HBS (A-D) or a similar medium in which Na+ was replaced with NMDG (E, 
F) containing 200 µM CaCl2 and preincubated with 3 µM Gö6976 or its vehicle, DMSO, for 
10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM EGTA and the 
platelets stimulated with 50 µM ADP (A, B) or 0.5 units ml-1 thrombin (C-F) and either both 
1 µM thapsigargin and 20 µM TBHQ (TGT; B, D, F), or an equal volume of their vehicle, 





 Fig. 11. The novel PKC isoform (PKCθ/δ inhibitor) does not potentiate ADP- or thrombin-
evoked rises in [Ca2+]cyt. (A) Fura-2-loaded human platelets were suspended in supplemented HBS 
containing 200 µM CaCl2, and preincubated with 100 nM, 300 nM, 1 µM or 3 µM PKCθ/δ inhibitor 
or its vehicle, DMSO, for 10 min at 37°C. Extracellular Ca2+ was then chelated by addition of 1 mM 
EGTA before the platelets were stimulated with 50 µM ADP. (B, C) Fura-2-loaded human platelets 
were suspended in supplemented HBS containing 200 µM CaCl2, and preincubated with 300 nM 
PKCθ/δ inhibitor, 3 µM Gö6976, both inhibitors or their vehicle, DMSO, for 10 min at 37°C. 
Extracellular Ca2+ was then chelated by addition of 1 mM EGTA before the platelets were stimulated 
with 50 µM ADP (B) or 0.5 units ml-1 thrombin. Results are expressed as mean of percentage control 







Fig. 12. Model for proposed effects of PKC in controlling ADP- and thrombin-evoked Ca2+ 
signalling in human platelets. The agonist-evoked rise in [Ca2+]cyt is controlled by the 
conventional protein kinase C isoforms, PKCα and PKCβ, by altering the rate of Ca2+ 
removal into the extracellular fluid and Ca2+ sequestration into intracellular stores in an 
agonist-dependent manner. Upon ADP activation, PKC negatively regulates the Ca2+ signal 
by increasing Ca2+ sequestration back into the dense tubular system through activation of 
SERCA. Upon thrombin stimulation, PKC additionally regulates Ca2+ removal from the 
cytosol into the extracellular space by increasing the activity of the Na+/K+-ATPase. This in 
turn limits agonist-evoked rises in [Na+]cyt, which slows Ca
2+ efflux via forward mode 
Na+/Ca2+ exchange. 
 
 
